Robert Zeldin

Robert Zeldin

Directeur Technique/Scientifique/R&D chez MEIRAGTX HOLDINGS PLC

Fortune : 2 M $ au 30/06/2026

63 ans
Health Technology
Consumer Services
Government

Profil

Robert K.
Zeldin
is currently Chief Medical Officer at MeiraGTx Holdings Plc since 2020.
Former positions include Chief Medical Officer & Executive Vice President at Acceleron Pharma, Inc. from 2018 to 2019; Chief Medical Officer at Immunovant, Inc. from 2019 to 2020; Chief Medical Officer at Ablynx NV from 2015 to 2018; Senior Vice President-Global Clinical Development at Stallergenes SAS from 2011 to 2015; Vice President at Novartis Pharmaceuticals Corp.
from 2005 to 2010; and Medical Officer roles at the US Food & Drug Administration and the Center for Biologics Evaluation & Research.
Education includes undergraduate studies at The Johns Hopkins University and a doctorate from Tufts University School of Medicine.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
25/06/2026 171 801 ( 0,19 % ) 2 M $ 30/06/2026

Postes actifs de Robert Zeldin

SociétésPosteDébut
MEIRAGTX HOLDINGS PLC Directeur Technique/Scientifique/R&D 05/08/2020

Anciens postes connus de Robert Zeldin

SociétésPosteFin
IMMUNOVANT, INC. Directeur Technique/Scientifique/R&D 01/04/2020
ACCELERON PHARMA INC. Directeur Technique/Scientifique/R&D 05/04/2019
ABLYNX Directeur Technique/Scientifique/R&D 01/01/2018
STALLERGENES Directeur Technique/Scientifique/R&D 01/01/2015
Corporate Officer/Principal 01/01/2010
Voir l'expérience en détail de Robert Zeldin

Formation de Robert Zeldin

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

54

Relations au 1er degré

10

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées10

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Government

Commercial Services

Consumer Services

Health Technology

Health Technology

  1. Bourse
  2. Insiders
  3. Robert Zeldin
🔇